PPF and SOTIO Invest $6.5 Million in MaveriX Oncology and its Lead Program MVX-5005
SOTIO, together with PPF, and MaveriX Oncology, Inc., today announce the investment of PPF Group in MaveriX Oncology Inc., a private biotech company with a proprietary pipeline of targeted, small-molecule cancer chemo-immunotherapeutics. PPF has committed to investing $6.5 million in MaveriX Oncology’s ongoing Series A financing contingent on key development milestones. In total, MaveriX is aiming to secure a total of $20 million in funding and the round will remain open for additional investors to join. The proceeds will enable MaveriX to advance the company’s lead program MVX-5005 through IND-enabling studies, and complete first-in-human Phase Ia/Ib clinical trials for the treatment of solid tumors in support of clinical proof-of-concept. The company will also advance further platform programs to drug candidate selection.
In addition, SOTIO has secured an option to license and co-develop MVX-5005 and related next-generation compounds in Europe, contingent on completion of the first phase I trial. Upon exercise of the option, MaveriX and SOTIO will collaborate and share the costs for development of MVX-5005 and MaveriX will become eligible to receive up to $138 million in development, regulatory and commercial milestones if MVX-5005 is successfully developed in multiple cancer indications in Europe. Further terms on the investment and option to license are not disclosed.
MVX-5005 has been designed to selectively kill cancer cells and eradicate immune suppressive cell subsets known to cause resistance to chemotherapy and immunotherapy. MVX-5005 utilizes a proprietary targeting and activation scaffold, a Small-Molecule Drug Conjugate (SMDC) to improve on the clinical safety and efficacy of a DNA damaging agent which exhibits broad anti-tumor activity including immunomodulatory and immunostimulatory properties. Pre-clinical studies have shown that MVX-5005 exhibits broad single agent anti-tumor activity with a favorable safety profile. MVX-5005 is currently in formal IND-enabling studies. MaveriX anticipates initiating a Phase I clinical study by the end of Q4 2020.
Through the investment, MaveriX will also advance several of its innovative pipeline programs based on the SMDC platform conjugated to other established or novel therapeutics.
Dr. Steven Everett, President and CEO of MaveriX Oncology, said: “We are grateful to the PPF Group for leading the Series A round as we advance our lead program MVX-5005 into the clinic and continue to expand our differentiated SMDC platform. The strong support of PPF and SOTIO enables us to achieve our next step of growth as we aim to quickly bring new and improved treatment options to patients that suffer from cancer.”
Dr. Daniel Von Hoff, Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, said: “The preclinical data of the lead program of MaveriX is encouraging. Overcoming some of the limitations of current chemotherapy as exemplified by MVX-5005 has great potential across many solid tumors. Together with our experts at TD2, we are very pleased to support development efforts of MaveriX to bring better cancer treatments to patients in need.”
Dr. Radek Špíšek, Chief Executive Officer of SOTIO, said: “We believe that the MaveriX SMDC technology approach enables the selective delivery of potent anti-cancer agents directly to tumors. A depleting effect of MVX-5005 on the immunosuppressive cells in the tumor microenvironment represents an additional mechanism of action and indicates that MVX-5005 might act as an efficient chemo-immunotherapy. We are very much looking forward to supporting MaveriX in its efforts to build an innovative oncology company developing first-in-class anticancer agents.”
As part of the agreement, Dr. Norbert Prenzel, Head of Business Development and Licensing of SOTIO, will join the board of directors of MaveriX Oncology Inc.
Please find the full release online at: https://www.sotio.com/news-publications/news.
Head of Communications
T: +420 224 174 448
M: +420 603 280 971
Communication representative of MaveriX Oncology, Inc.
Senior Director, IR, MacDougall
T: +1(781) 591-3443
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AskNicely Opens Amsterdam Office To Meet Growing Demand in Europe22.1.2020 23:05:00 EET | Press release
AskNicely, the customer experience platform for people-powered businesses, today announced the opening of its first European office in Amsterdam. The company is headquartered in Portland, Oregon and recently expanded its original office in Auckland, New Zealand. “Amsterdam has become a hub for innovation,” said AskNicely co-founder and CEO Aaron Ward. “We recognize the potential of the city’s incredible talent pool, its world-class infrastructure, and the vibrant growth that has fueled the Amsterdam tech scene.” The European office was added in response to customer demand, and to accelerate the company’s growth plans. In 2019, AskNicely raised $10 million in Series A funding and expanded on its core NPS software by launching the world’s first mobile customer experience coaching app, which helps companies consistently deliver on their brand promise by using real-time feedback to coach employees. “I am delighted that AskNicely has chosen to set up its operations in the Netherlands and ho
Strong Revenue Growth in 2019 and Promising Outlook22.1.2020 19:45:00 EET | Press release
Kalray (Paris:ALKAL) (Euronext Growth Paris : ALKAL), a pioneer in processors for new intelligent systems, reviews its business in the second half of 2019 (from July 1 to December 31, 2019) and looks back over the highlights of the period. Eric Baissus, President of Kalray’s Executive Board, commented as follows: “2019 was a pivotal year for Kalray marked by the achievement of a number of key milestones. First of all, we finished developing our 3rd generation Coolidge™ processor and presented it for the first time in early January at CES. Mass production is scheduled to start second semester of 2020. Furthermore, strategic agreements were signed with top-tier players including NXP, Wistron, 2CRSI and Intron Technology, which will boost our credibility and accelerate time to market for Coolidge™. Our target of achieving revenues of €100 million by 2022 have been confirmed by the initial performances of Coolidge™, the industry enthusiasm which we were able to measure at CES and the numer
PMI Salary Survey Reveals Project Management Practitioners with the PMP Certification Earn 22% More22.1.2020 19:30:00 EET | Press release
The Project Management Institute (PMI) today released its “Earning Power: Project Management Salary Survey” which reveals a significant advantage in earning potential for practitioners who hold the Project Management Professional (PMP)® certification. According to the survey, respondents with a PMP certification reported higher median salaries than those without a PMP certification -- 22% higher on average across the 42 countries surveyed. New in this edition is salary information from five countries not previously covered— Indonesia, Pakistan, the Philippines, Portugal and the Russian Federation. The 11th edition of the survey incorporates information from more than 32,000 project management practitioners in 42 countries across the globe. The comprehensive biennial survey offers insight into the value of project management skills, experience and certifications. It is an industry-leading source of data, giving project management practitioners a greater awareness of their earning potent
Philip Morris International Wins 2020 BIG Innovation Award22.1.2020 18:05:00 EET | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that it has won the 2020 BIG Innovation Award in the “Organization” category. The company was honored for placing innovation front and center as it continues its full-scale business transformation to deliver a smoke-free future and replace cigarettes with better alternatives for those adults who would otherwise continue to smoke. The BIG Innovation Awards, presented by the Business Intelligence Group, recognize organizations, products and people who bring new ideas to life. Organizations from across the globe submitted their recent innovations for consideration, and nominations were judged by a select group of business leaders and executives. “It is gratifying to continue to be recognized by the broader business community for the innovation that is fueling our progress toward a smoke-free future,” said Jacek Olczak, PMI’s chief operating officer. “As we are undergoing the largest transformation in our company’s history,
Sevan Refreshes 14,000th Restaurant22.1.2020 17:00:00 EET | Press release
Sevan Multi-Site Solutions, Inc. (Sevan)—a global leader in innovative design, program management, construction services and data analytics—just finished refreshing their 14,000th restaurant. For eight years, Sevan has provided solutions for the world’s largest brands while accelerating development programs across the United States and Canada for multi-site clients. Sevan has partnered on restaurant programs with Carl’s Jr., Carrols Corporation (a Burger King franchisee), Chipotle, McDonald’s, Panera, Starbucks, Taco Bell, Army & Air Force Exchange Service (Exchange) restaurants and others. Sevan’s Chief Revenue Officer Jim Furis says working with great clients is the best part of the company’s success in the Quick Service Restaurant (QSR) world. “Each client is unique and their project execution style varies widely. Not surprisingly, they all share one objective—to deliver a fantastic customer experience in a reliable way at loads of locations,” Furis said. “Sevan is proud to have pla
Mary Kay Inc. Celebrates Milestone Anniversaries Around the World22.1.2020 16:50:00 EET | Press release
Blow out the pink candles and make a wish—in 2020, Mary Kay Inc. will celebrate milestone anniversaries in some of its most important markets around the globe. The iconic Mary Kay Ash, with humble roots in small town, Texas, founded her namesake brand in 1963. The brand quickly developed into a worldwide phenomenon with millions of independent beauty consultants in nearly 40 countries. While beauty trends come and go, Mary Kay owes its staying power to something that never goes out of style: female empowerment and a greater purpose to do good. “While our innovative skin care, on-trend color cosmetics, fragrances and body care products have been loved for more than 56 years by millions of consumers around the world, our company was founded with much more than lipstick in mind,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “Our founder, Mary Kay Ash, built her dream company with two goals: create economic independence for women through entrepreneurship, and make the world a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom